

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO.

09/463,733

00/00/00

ZUKER

Ü

02307E-08511

HM22/0423

ANNETTE S PARENT TOWNSEND AND TOWSEND AND CREW TWO EMBARCADERO CENTER 8TH FLOOR SAN FRANCISCO CA 94111 HOUTTEMAN.S

ART UNIT PAPER NUMBER

EXAMINER

1656

DATE MAILED:

04/23/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Office Action Summary

Application No.

09/463,733

Zuker et al.

Examiner

Scott Houtteman

Art Unit 1656



-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address -Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE <u>three</u> MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). 1) Responsive to communication(s) filed on _____ 2b) X This action is non-final. 2a) This action is FINAL. 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quay/1935 C.D. 11; 453 O.G. 213. **Disposition of Claims** is/are pending in the applica 4) X Claim(s) 1-38 4a) Of the above, claim(s) ______ is/are withdrawn from considera is/are allowed. 5) Claim(s) ___ is/are rejected. 6) X Claim(s) 1-38 is/are objected to. 7) Claim(s) are subject to restriction and/or election requirem 8) 🗌 Claims _ **Application Papers** 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on ______ is/are objected to by the Examiner. 11) The proposed drawing correction filed on ______ is: a pproved b) disapproved 12) \square The oath or declaration is objected to by the Examiner. Priority under 35 U.S.C. § 119 13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d). a) All b) Some* c) None of: 1.

Certified copies of the priority documents have been received. 2.
Certified copies of the priority documents have been received in Application No. _ 3.

Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). *See the attached detailed Office action for a list of the certified copies not received. 14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e). Attachment(s) 18) Interview Summary (PTO-413) Paper No(s). 15) Notice of References Cited (PTO-892) 19) Notice of Informal Patent Application (PTO-152) 16) Notice of Draftsperson's Patent Drawing Review (PTO-948) 17) X Information Disclosure Statement(s) (PTO-1449) Paper No.(s). 5/30/00 20) Other:

1. Claims 1-38 are rejected under 35 U.S.C. § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 1-38 are drawn to methods and kits for "screening *in vivo*" and screening *in vitro*" for signal transduction modulators for a G-protein coupled receptor. The steps of the method, however, recite detecting modulation of RDGC GPCR phosphatase activity. It is unclear whether this is a screen for modulation of the phosphatase activity or signal transduction. Amendment is requested to either change the preamble to recite phosphatase modulation or to add a step explaining how the modulation of phosphatase in interpreted to determine modulation of signal transduction

- 2. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 3. Claims 1-38 are rejected under 35 U.S.C. § 103(a) as being unpatentable over Vinós et al.. Science, 277:687-690, 8/1/996 (Vinós).
- 4. Vinós teaches a method of in vivo and in vitro modulation of the RDGC phosphatase activity. (Fig. 1, Panel B, for example). The claimed "compound suspected of having modulation activity" reads on the rdgC mutants which modulate phosphatase activity. See for example Fig. 3,

Serial No. 09/463,733 Art Unit 1656

caption. The claims differ from the prior art in the recitation of "screening" and methods of modulation.

It would, however, have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made to interpret the deactivation taught by Vinós as "modulation" because, modulation is defined in the specification "the invention includes . . . defective GPCR phosphatases."

5. Papers relating to this application may be submitted to Technology Center 1600 by facsimile transmission. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The Technology Center 1600 Fax numbers are (703) 305-3014 and 308-4242.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Scott Houtteman whose telephone number is (703) 308-3885. The examiner can normally be reached on Tuesday-Friday from 8:30 AM - 5:00 PM. The examiner can also be reached on alternate Mondays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, W. Gary Jones, can be reached at (703) 308-1152.

Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center receptionist whose telephone number is (703) 308-0196.

Scott Houtteman March 20, 2000

SCOTT W. HOUTTEMAN PRIMARY EXAMINER